Holen Sie sich die Stockscreener-App
3.14
0.48%
-0.015
Schlusskurs vom Vortag:
$3.155
Offen:
$3.1442
24-Stunden-Volumen:
5,850
Relative Volume:
0.32
Marktkapitalisierung:
$4.93M
Einnahmen:
$8.62M
Nettoeinkommen (Verlust:
$-6.15M
KGV:
-0.2847
EPS:
-11.03
Netto-Cashflow:
$-5.32M
1W Leistung:
-4.85%
1M Leistung:
+42.73%
6M Leistung:
-26.29%
1J Leistung:
-44.44%
1-Tages-Spanne:
$3.115
$3.21
1-Wochen-Bereich:
$3.00
$3.33
52-Wochen-Spanne:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Firmenname
Evoke Pharma Inc
Sektor
Telefon
858-345-1494
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Vergleichen Sie EVOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
3.14 | 4.93M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
160.41 | 66.72B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.45 | 48.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 47.74B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.48 | 18.49B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.07 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | Fortgesetzt | FBR & Co. | Buy |
| 2017-03-16 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-01-30 | Hochstufung | Laidlaw | Neutral → Buy |
| 2017-01-05 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | Bestätigt | Rodman & Renshaw | Neutral |
| 2016-07-19 | Bestätigt | FBR Capital | Outperform |
| 2016-07-19 | Herabstufung | Noble Financial | Buy → Hold |
| 2016-07-18 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | Eingeleitet | Northland Capital | Outperform |
| 2016-03-14 | Bestätigt | Ascendiant Capital Markets | Buy |
| 2016-02-17 | Fortgesetzt | FBR Capital | Outperform |
| 2014-12-03 | Bestätigt | MLV & Co | Buy |
| 2014-11-07 | Eingeleitet | MLV & Co | Buy |
| 2014-04-22 | Eingeleitet | Laidlaw | Buy |
| 2013-11-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus
Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times
Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire
Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World
FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World
Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech
Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal
Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World
Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Evoke Pharma (NASDAQ:EVOK) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com - Defense World
Bleichroeder LP Significantly Reduces Stake in Evoke Pharma Inc - GuruFocus
Bleichroeder LP's Strategic Acquisition of Evoke Pharma Inc Shar - GuruFocus.com
Evoke Pharma stock hits 52-week low at $3.4 amid challenges - Investing.com Australia
Evoke Pharma stock hits 52-week low at $3.4 amid challenges By Investing.com - Investing.com South Africa
Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower - Simply Wall St
Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
Earnings call transcript: Evoke Pharma Q4 2024 reports strong sales growth - Investing.com Australia
Evoke Pharma’s Earnings Call Highlights Revenue Growth and Strategic Partnerships - TipRanks
Evoke Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo
Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):